{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:40:02Z","timestamp":1739839202076,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01350-0","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T08:40:44Z","timestamp":1739004044000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design Overview"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R.","family":"Ingram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Geissb\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Haeberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahrukh","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Andr\u00e9","family":"Becherel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"1","key":"1350_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1350_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"5","key":"1350_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annder.2018.01.043","volume":"145","author":"J Loget","year":"2018","unstructured":"Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, et al. Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study. Ann Dermatol Venereol. 2018;145(5):331\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"1350_CR4","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1350_CR5","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/jdv.13687","volume":"30","author":"V Bettoli","year":"2016","unstructured":"Bettoli V, Pasquinucci S, Caracciolo S, Piccolo D, Cazzaniga S, Fantini F, et al. The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol. 2016;30(11):1965\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1350_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1350_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjmed.2022.09.025","volume":"136","author":"A Garg","year":"2023","unstructured":"Garg A, Naik HB, Kirby JS. A practical guide for primary care providers on timely diagnosis and comprehensive care strategies for hidradenitis suppurativa. Am J Med. 2023;136(1):42\u201353.","journal-title":"Am J Med"},{"key":"1350_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.04.025","volume":"283","author":"MS Bauer","year":"2020","unstructured":"Bauer MS, Kirchner J. Implementation science: what is it and why should I care? Psychiatry Res. 2020;283: 112376.","journal-title":"Psychiatry Res"},{"key":"1350_CR9","unstructured":"Martorell A, Becherel P-A, Ingram J, Kokolakis G, McGrath B, Romanelli M, et al. HELyx: A study to assess the effectiveness and feasibility of implementation strategies to improve the diagnosis and management of patients with hidradenitis suppurativa: Study design overview. The European Academy of Dermatology and Venereology (EADV) Congress, Berlin, Germany, 11\u201314 October, 2023 [P0016]. 2023."},{"issue":"3","key":"1350_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217\u201326.","journal-title":"Med Care"},{"key":"1350_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292: 114523.","journal-title":"Soc Sci Med"},{"issue":"5","key":"1350_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1350_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","volume":"154","author":"S Hessam","year":"2018","unstructured":"Hessam S, Scholl L, Sand M, Schmitz L, Reitenbach S, Bechara FG. A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol. 2018;154(3):330\u20135.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1350_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamadermatol.2023.0797","volume":"159","author":"A Garg","year":"2023","unstructured":"Garg A, Zema C, Ciaravino V, Rolleri R, Peterson L, Garcia L, et al. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: a novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials. JAMA Dermatol. 2023;159(6):606\u201312.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1350_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.clindermatol.2023.08.016","volume":"41","author":"NDK Koerts","year":"2023","unstructured":"Koerts NDK, Bouwman K, Prens LM, Horv\u00e1th B. Assessment tools and phenotype classification for hidradenitis suppurativa. Clin Dermatol. 2023;41(5):601\u201310.","journal-title":"Clin Dermatol"},{"issue":"5","key":"1350_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjd.19565","volume":"184","author":"N Goldfarb","year":"2021","unstructured":"Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. Br J Dermatol. 2021;184(5):905\u201312.","journal-title":"Br J Dermatol"},{"key":"1350_CR17","volume-title":"Dermatologic surgery: principles and practice","author":"H Hurley","year":"1996","unstructured":"Hurley H. Hidradenitis suppurativa. In: Roenigk RK, Roenigk HH Jr, editors. Dermatologic surgery: principles and practice. 2nd ed. New York: Marcel Dekker; 1996.","edition":"2"},{"issue":"3","key":"1350_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1350_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149\u201358.","journal-title":"Pain"},{"issue":"9","key":"1350_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1350_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2340\/00015555-2642","volume":"97","author":"A Reich","year":"2017","unstructured":"Reich A, Chatzigeorkidis E, Zeidler C, Osada N, Furue M, Takamori K, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol. 2017;97(6):759\u201360.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1350_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Thorlacius L, Villumsen B, Ingram JR, Garg A, Christensen KB, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183(2):340\u20138.","journal-title":"Br J Dermatol"},{"key":"1350_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jdin.2022.11.003","volume":"10","author":"A Alavi","year":"2023","unstructured":"Alavi A, Anand N, Yamanaka-Takaichi M, Piguet V, Simmers J, Machado M, et al. Evaluating the hidradenitis odor and drainage scale (HODS): a new validated potential instrument to assess odor and drainage in hidradenitis suppurativa\u2014a cross-sectional study. JAAD Int. 2023;10:75\u20136.","journal-title":"JAAD Int"},{"issue":"4","key":"1350_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bjd.19344","volume":"184","author":"JS Kirby","year":"2021","unstructured":"Kirby JS, Hereford B, Thorlacius L, Villumsen B, Ingram JR, Garg A, et al. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa. Br J Dermatol. 2021;184(4):681\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1350_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"GPP","year":"2016","unstructured":"GPP. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1350_CR26","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163\u201394.","journal-title":"Ann Intern Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01350-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01350-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01350-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:56Z","timestamp":1739837456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01350-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01350-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Martorell, Pierre-Andr\u00e9 Becherel, John R. Ingram, Barry M. McGrath, and Marco Romanelli have received honoraria for their participation in the global HS Implementation Science working group. John R. Ingram\u00a0has acted as a consultant and\/or advisory board member for Abbvie, Novartis, UCB\u00a0Pharma, ChemoCentryx, Boehringer Ingelheim, Insmed, Viela Bio, MoonLake, Union Therapeutics, and Kymera Therapeutics; he also received an editorial stipend from the British Journal of Dermatology as Editor-in-Chief and an author honorarium from UpToDate and is co-copyright holder of HiSQoL and Investigator and Patient Global Assessment instruments for HS. John R.\u00a0Ingram\u2019s department received royalties from the DLQI and related instruments. Georgios Kokolakis is or has acted as a speaker and\/or advisory board member for honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Bayer, Biogen IDEC, Boehringer, Bristol-Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Lilly, MSD, Mylan, Novartis, Parexel, Pfizer, Sanofi, Sharpe and Dohme, Takeda and UCB\u00a0Pharma. Barry M. McGrath has received disease-related consultancy\/advisory board honoraria from Incyte, Novartis and UCB\u00a0Pharma. Marco Romanelli has received financial support for lectures, consultations and\/or research studies from the following companies: AbbVie, Almirall, Bristol Myers Squib, ConvaTec, Eli Lilly, Janssen Cilag, KLOX Technologies, Novartis, Paul Hartmann, Sanofi Genzyme and Urgo. Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and\/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Incyte Corporation, JanssenCilag GmbH, Johnson & Johnson, Merck, M\u00f6lnlycke, MoonLake, Novartis Pharma GmbH, Sanofi, Sitala, UCB Pharma and Dr. Wolff. Antonio Martorell has received honoraria and\/or travel grants and\/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB\u00a0Pharma, Lilly, LEO Pharma, L\u2019Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squib and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB\u00a0Pharma, Jansen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, and Novartis. Mona Biermann, Yvonne Geissb\u00fchler, Benjamin M. Haeberle, Mahrukh Zahid, Michael Fritz are stakeholders and\/or employees of Novartis Pharma AG. Erhard Quebe-Fehling was an employee of Novartis Pharma AG at the time of study development and is now retired, currently a Statistical Consultant at Cogitars GmbH. Craig Richardson was an employee of Novartis Pharma AG at the time of study development and is now retired. Pierre-Andr\u00e9 Becherel has received consulting fees from Novartis, AbbVie, Pfizer, and UCB\u00a0Pharma; payment or honoraria from Novartis and AbbVie; support for attending meetings or travel from Novartis; and served on a Data Safety Monitoring Board or Advisory Board for Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics committee approval was not required in Germany for this study, as only anonymized data from patients are collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}